What Monopar Therapeutics's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 25 | 27 |
| Total trades | 45 | 64 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 68,099 | 119,960 |
| Disposed | 58,986 | 122,496 |
| Net activity | +9,113 | −2,536 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Tsuchimoto Kim R | Director | Nov 04 | Open-market sale · S | −600 | $72.21 | −$43.3K | 0 |
| Tsuchimoto Kim R | Director | Nov 04 | Open-market sale · S | −996 | $71.35 | −$71.1K | 600 |
| Tsuchimoto Kim R | Director | Nov 04 | Open-market sale · S | −1,295 | $70.75 | −$91.6K | 1,596 |
| Tsuchimoto Kim R | Director | Nov 04 | Exercise / conversion · M | +2,035 | $14.00 | +$28.5K | 2,891 |
| Tsuchimoto Kim R | Director | Nov 04 | Exercise / conversion · M | +856 | $30.00 | +$25.7K | 856 |
| Anderson Raymond | Director | Nov 02 | Open-market sale · S | −1,502 | $70.04 | −$105K | 5,373 |
| Anderson Raymond | Director | Nov 02 | Open-market sale · S | −200 | $68.68 | −$13.7K | 6,875 |
| Anderson Raymond | Director | Nov 02 | Open-market sale · S | −600 | $67.06 | −$40.2K | 7,075 |
| Anderson Raymond | Director | Nov 02 | Open-market sale · S | −840 | $66.16 | −$55.6K | 7,675 |
| Anderson Raymond | Director | Nov 02 | Exercise / conversion · M | +1,740 | $30.00 | +$52.2K | 8,515 |
| Anderson Raymond | Director | Nov 02 | Exercise / conversion · M | +1,402 | $30.00 | +$42.1K | 6,775 |
| Tsuchimoto Kim R | Director | Nov 02 | Open-market sale · S | −1,199 | $70.10 | −$84K | 0 |
| Tsuchimoto Kim R | Director | Nov 02 | Exercise / conversion · M | +1,199 | $30.00 | +$36K | 1,199 |
| Robinson Chandler | Chief Executive Officer | Oct 20 | Withheld — tax / exercise cost · F | −597 | $92.59 | −$55.3K | 104,127 |
| Starr Christopher M | Director | Oct 01 | Open-market sale · S | −799 | $79.67 | −$63.7K | 5,173 |
| Starr Christopher M | Director | Oct 01 | Open-market sale · S | −2,970 | $78.82 | −$234K | 5,972 |
| Starr Christopher M | Director | Oct 01 | Open-market sale · S | −4,631 | $78.09 | −$362K | 8,942 |
| Starr Christopher M | Director | Oct 01 | Exercise / conversion · M | +8,400 | $0.01 | +$42 | 13,573 |
| Robinson Chandler | Chief Executive Officer | Sep 30 | Withheld — tax / exercise cost · F | −4,344 | $79.67 | −$346K | 104,724 |
| Robinson Chandler | Chief Executive Officer | Sep 30 | Exercise / conversion · M | +9,801 | — | — | 109,068 |
Loading...